SCHEMBL1081012

SCHEMBL1081012

CCOC(=O)Cc1ccc(C)c(OCc2c(C)cccc2C)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 3/20 0.74
PPARG P37231 2/20 0.43
PPARA Q07869 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
NPC1 O15118 1/20 0.41
PKM P14618 1/20 0.41
NFKB1 P19838 1/20 0.41
RAB9A P51151 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
RXRG P48443 1/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1007810 0.89 SLC22A12 (0.58) SLC22A12PPARGPPARASMN1; SMN2MEN1
SCHEMBL1584780 0.86 SLC22A12 (0.55) SLC22A12L3MBTL1NPC1PKMNFKB1
SCHEMBL1584983 0.85 SLC22A12 (0.54) SLC22A12SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL460443 0.85 SLC22A12 (1.00) SLC22A12NFKB1RXRARXRBRXRG
SCHEMBL1010327 0.83 SLC22A12 (0.50) SLC22A12PPARGPPARAL3MBTL1TSHR
SCHEMBL3094003 0.82 SLC22A12 (0.49) SLC22A12PPARGPPARAL3MBTL1SMN1; SMN2
SCHEMBL18297332 0.79 DRD2 (0.53) SLC22A12L3MBTL1NPC1PKMNFKB1
SCHEMBL31594790 0.79 ALDH1A1 (0.49) L3MBTL1NPC1PKMNFKB1RAB9A
SCHEMBL1008089 0.79 ALDH1A1 (0.49) L3MBTL1NPC1PKMNFKB1RAB9A
SCHEMBL1008570 0.78 TBXAS1 (0.51) SLC22A12PPARGPPARAL3MBTL1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 EP disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US disclosed
EP-2268141-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2011-01-05 EP disclosed
WO-2009151695-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID RCC2, HAX1, SLC10A6 SLC22A12 139/4885PPARG 2231/4885PPARA 1930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.